TSX Exchange Symbol: RVX
CALGARY, Oct. 8, 2014 /CNW/ - Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced that, at its annual meeting of shareholders held on October 8, 2014, each of the five nominees proposed as a director and listed in its management information circular dated August 25, 2014 (the "Information Circular") were elected as directors. Proxy voting results for each nominee are set out below:
|
Votes For
|
Votes Withheld
|
% For
|
% Withheld
|
Donald J. McCaffrey
|
19,598,577
|
272,713
|
(98.63%)
|
(1.37%)
|
Peter Johann
|
19,735,454
|
135,836
|
(99.32%)
|
(0.68%)
|
Kelly McNeill
|
19,598,354
|
272,936
|
(98.63%)
|
(1.37%)
|
Kenneth Zuerblis
|
19,745,389
|
125,901
|
(99.37%)
|
(0.63%)
|
Eldon Smith
|
19,618,789
|
252,501
|
(98.73%)
|
(1.27%)
|
About Resverlogix
Resverlogix Corp. (TSX:RVX) is a clinical stage cardiovascular company developing compounds involving a therapeutic increase in ApoA-1. RVX-208 is a first in-class small molecule for the treatment of atherosclerosis and other chronic diseases such as Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information, please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.
Company Contacts:
|
|
|
|
Donald J. McCaffrey
|
Sarah Zapotichny
|
President and CEO
|
Director, Investor Relations
|
Resverlogix Corp.
|
Resverlogix Corp.
|
Phone: 403-254-9252
|
Phone: 403-254-9252
|
Email: don@resverlogix.com
|
Email: sarah@resverlogix.com
|
SOURCE Resverlogix Corp.
Copyright CNW Group 2014